Zai Lab Ltd. (ZLAB) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$23.86

From 52W high−17.46%

Volume383605.00

Market cap$2.70B

P/E (TTM)—

P/S (TTM)6.0x

Div yield—

Key dataOct 19, 2026

Open

$23.86

From 52W high

−17.46%

Volume

383605.00

Market cap

$2.70B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.9x

P/E (TTM)

—

RSI (14)

46.5

MomentumView details →

1D Return

+3.75%

YTD Return

+36.25%

SummaryUpdated Jun 1, 2026

Zai Lab Limited (NASDAQ:ZLAB) is a Chinese biopharmaceutical company founded in 2013 and headquartered in Shanghai. The company went public on NASDAQ in September 2017. Zai Lab has evolved from a pure licensing and development company into a commercial-stage biopharmaceutical enterprise with a growing portfolio of marketed products and an extensive pipeline of investigational therapies. The company focuses primarily on bringing innovative medicines to patients in China and other Asian markets, while also developing select assets for global markets.

Ask drillr about Zai Lab Ltd. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−13.9x

EV/Sales

5.2x

P/S (TTM)

6.0x

P/B (TTM)

4.4x

ProfitabilityView details →

Gross Margin

56.47%

Net Margin

−41.86%

EBITDA Margin

−37.54%

ROE (TTM)

−31.01%

ROA (TTM)

−17.51%

Asset Turnover

0.41x

GrowthView details →

Revenue YoY

+5.10%

EPS YoY

+69.76%

FCF YoY

+28.52%

Revenue CAGR 3Y

+28.86%

EPS CAGR 3Y

+38.46%

EBITDA YoY

+12.54%

MomentumView details →

1D Return

+3.75%

YTD Return

+36.25%

1Y Return

−16.37%

RSI (14)

46.5

vs 50D SMA

−5.10%

vs 200D SMA

+15.86%

Capital & dividendView details →

Debt/Equity

0.42x

Current Ratio

2.13x

Quick Ratio

1.92x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.46

EPS Surprise

32.29%

Beats (12Q)

4/12

Next Q EPS Est

−$0.62

Avg Surprise (4Q)

5.62%

Rev Surprise

2.35%

Financials snapshotView financials →

Revenue (TTM)

449.61M

Net Income (TTM)

−188.21M

Op. CF (TTM)

−133.38M

Next earningsNov 5, 2026 →

Latest newsMore news →

Zai Lab announced that data from the first clinical trial of its ZL-1503 antibody will be presented at the ACAAI 2026 Annual Scientific Meeting in Phoenix.6d ago

US-listed Chinese stocks weakened, with the Nasdaq Golden Dragon China Index down 0.67% and names including Hichain Securities, Yatsen E-Commerce, Zhineng Weilai, So-Young, Zai Lab, Baidu and Pinduoduo declining.25d ago

Similar companies

Nurix Therapeutics, Inc.NRIX Genor Biopharma Holdings Limited06998.HK Soleno Therapeutics, Inc.SLNO Celcuity Inc.CELC Arcus Biosciences, Inc.RCUS Enliven Therapeutics, Inc.ELVN Find similar companies →

Latest newsMore news →

Zai Lab announced that data from the first clinical trial of its ZL-1503 antibody will be presented at the ACAAI 2026 Annual Scientific Meeting in Phoenix.6d ago US-listed Chinese stocks weakened, with the Nasdaq Golden Dragon China Index down 0.67% and names including Hichain Securities, Yatsen E-Commerce, Zhineng Weilai, So-Young, Zai Lab, Baidu and Pinduoduo declining.25d ago